Lawrence Schiller, MD, FACP, FACG
Professor of Medicine
Texas A&M College of Medicine
Baylor University Medical Center Campus
Reach MD / podcast
This activity will review the safety and efficacy of available therapies to prevent and treat opioid-induced constipation. It will also examine strategies for optimizing treatment selection and adjusting therapy when necessary to help patients achieve their treatment goals and improve their overall quality of life.
This activity is intended for primary care physicians and other clinicians involved in the management of patients with constipation, including NPs and PAs.
Upon completion of this educational activity, the participant should be able to:
- Develop evidence-based individualized treatment plans for patients with OIC.
- Adjust treatment plans for OIC as needed to achieve treatment goals.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Schiller discloses that he has served on Speakers Bureaus for AstraZeneca, Takeda/Sucampo, Valeant/Salix, and Actavis/Forest/Ironwood. He has served as a consultant for AstraZeneca, Actavis/Forest/Ironwood, Romark, and Janssen.
Penn State staff involved in the development and review of this activity have nothing to disclose.
Lilian McVey, MCM Education Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5876-16-T.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 30 minutes to complete.
Commercial Support Statements
This activity is supported by an educational grant from AstraZeneca.
ReachMD requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Chrome, Firefox or Safari. Users accustomed to IE8 and IE9 are advised to update their browsers for the best experience.
- Participants must listen to the podcast in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit.
- Credit will be awarded for a score of 80% or better and a statement of credit may be printed immediately after passing the post-test. There is no fee to participate in this activity.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or AstraZeneca. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.